Literature DB >> 27152039

Clinical presentation and management of suspected ribavirin toxicosis in a dog.

Kimberly Bridges1, Nicole Beckel1, Claire Sharp1, Laura Stern1.   

Abstract

A 5-month-old pit bull terrier was presented for evaluation of progressive lethargy, vomiting, diarrhea, and anorexia 45 hours after ingestion of 625 mg/kg body weight (BW) (9000 mg) of the antiviral medication, ribavirin. Abnormalities that were detected included dehydration, tachycardia, elevated liver enzymes, and prolonged prothrombin time. The dog was discharged after 5 days of aggressive supportive care consisting of intravenous fluids, antiemetics, gastroprotectants, hepatoprotectants, dextrose supplementation, and vitamin B/K1 supplementation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27152039      PMCID: PMC4827742     

Source DB:  PubMed          Journal:  Can Vet J        ISSN: 0008-5286            Impact factor:   1.008


  15 in total

1.  Ribavirin: a role in HIV infection?

Authors:  N Bodsworth; D A Cooper
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

2.  In vitro antiviral efficacy of ribavirin against feline calicivirus, feline viral rhinotracheitis virus, and canine parainfluenza virus.

Authors:  R C Povey
Journal:  Am J Vet Res       Date:  1978-01       Impact factor: 1.156

3.  Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions.

Authors:  S Khakoo; P Glue; L Grellier; B Wells; A Bell; C Dash; I Murray-Lyon; D Lypnyj; B Flannery; K Walters; G M Dusheiko
Journal:  Br J Clin Pharmacol       Date:  1998-12       Impact factor: 4.335

4.  Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology.

Authors:  S L Preston; G L Drusano; P Glue; J Nash; S K Gupta; P McNamara
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

5.  Aerosolized ribavirin-induced reversible hepatotoxicity in a hematopoietic stem cell transplant recipient with Hodgkin lymphoma.

Authors:  Jorge Chaves; Auris Huen; Carlos Bueso-Ramos; Amar Safdar; Saroj Vadhan-Raj
Journal:  Clin Infect Dis       Date:  2006-03-13       Impact factor: 9.079

Review 6.  What is the future of ribavirin therapy for hepatitis C?

Authors:  Christopher Koh; T Jake Liang
Journal:  Antiviral Res       Date:  2014-01-25       Impact factor: 5.970

Review 7.  The utility of therapeutic drug monitoring for ribavirin in patients with chronic hepatitis C--a critical review.

Authors:  Alice H W Chan; Nilufar Partovi; Mary H H Ensom
Journal:  Ann Pharmacother       Date:  2009-11-17       Impact factor: 3.154

Review 8.  Hepatotoxicity of antiretroviral therapy.

Authors:  Nickolas Kontorinis; Douglas Dieterich
Journal:  AIDS Rev       Date:  2003 Jan-Mar       Impact factor: 2.500

9.  In vitro efficacy of ribavirin against canine distemper virus.

Authors:  Gabriella Elia; Chiara Belloli; Francesco Cirone; Maria Stella Lucente; Marta Caruso; Vito Martella; Nicola Decaro; Canio Buonavoglia; Paolo Ormas
Journal:  Antiviral Res       Date:  2007-10-08       Impact factor: 5.970

10.  Toxicologic effects of ribavirin in cats.

Authors:  R C Weiss; N R Cox; M K Boudreaux
Journal:  J Vet Pharmacol Ther       Date:  1993-09       Impact factor: 1.786

View more
  1 in total

1.  Model based approach for estimating the dosage regimen of indomethacin a potential antiviral treatment of patients infected with SARS CoV-2.

Authors:  Roberto Gomeni; Tianhong Xu; Xuejuan Gao; Françoise Bressolle-Gomeni
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-05-20       Impact factor: 2.745

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.